Clinical Report: Expanding Optogenetics to Geographic Atrophy
Background
Geographic atrophy (GA) is a significant cause of irreversible vision loss associated with age-related macular degeneration (AMD). Current treatment options for GA are limited, making the exploration of innovative therapies like optogenetics crucial.
Data Highlights
No numerical data available in the source material.
Key Findings
- Sonpiretigene isteparvovec (MCO-010) has shown positive results in improving visual acuity in patients with retinitis pigmentosa.
- Improvements in vision have also been observed in Stargardt disease, particularly in patients with the macular phenotype.
- The safety profile of MCO-010 is reported to be good in both retinitis pigmentosa and Stargardt disease patients.
- A new model of GA in nonhuman primates demonstrated that MCO-010 could transfect 70% of the inner retinal layers.
- Clinical trials for GA using optogenetics are expected to commence soon.
Clinical Implications
Clinicians should stay informed about the upcoming clinical trials.
Conclusion
Continued research and clinical trials will be essential to determine the efficacy and safety of this approach.
Related Resources & Content
- Jordi Monés, MD, PhD, American Society of Retina Specialists, 2026 -- Expanding Optogenetics to Geographic Atrophy
- Retinal Physician, 2026 -- Dual-Pathway Gene Therapy for Geographic Atrophy
- The Ophthalmologist, 2026 -- The Optimism of Optogenetics for Vision Restoration
- Retinal Physician, 2026 -- The Therapeutic Pipeline for Geographic Atrophy
- Retinal Physician — Update on Optogenetics for Advanced Retinal Degenerations Recommendations
- Age-Related Macular Degeneration Preferred Practice Pattern® - Ophthalmology
- Standardizing Measurement of Complete Retinal Pigment Epithelial and Outer Retinal Atrophy: Classification of Atrophy Meeting Report 8 - Ophthalmology Retina
- Geographic atrophy in age-related macular degeneration: phenotypic characterisation for clinical trial consideration
- Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial - PubMed
- Real-World Experience With Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Age-Related Macular Degeneration - ScienceDirect
- Ocular Adverse Events Associated with Pegcetacoplan and Avacincaptad Pegol for Geographic Atrophy: A Population-Based Pharmacovigilance Study - ScienceDirect
- Efficacy of Intravitreal Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy - PubMed
- Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease - Nanoscope Therapeutics
- Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting
- ESCRS:MCO-010 Optogenetic Therapy for Vision Restoration
- Age-related macular degeneration: suitability of optogenetic therapy for geographic atrophy - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.